RBCC Anticipates Favorable Test Results of New Brain Injury Treatment

Posted: Published on May 31st, 2012

This post was added by Dr Simmons

NOKOMIS, Fla.--(BUSINESS WIRE)--

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), announced today that its latest joint venture target, Amarantus BioSciences, Inc. (AMBS), expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).

The study, commissioned late last year, is a collaboration between Amarantus and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI. The effects of TBI can be debilitating to athletes, combat veterans and others at risk of repetitive or serious head trauma. The recent death of NFL great Junior Seau, widely believed to be related to TBI, has focused a great deal of attention on the need for an effective treatment.

RBCC believes that Amarantus is close to developing that cure. The company expects the test results, scheduled to be announced next week, to show that Amarantus new protein therapy, MANF, effectively reduces cell death associated with TBI.

RBCC and Amarantus are currently wrapping up due diligence toward a potential joint venture agreement to develop and market MANF as a treatment for disorders associated with endoplasmic reticulum stress, including traumatic brain injury, Parkinsons disease, Alzheimers disease and other afflictions.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such asAmgen Inc.(NASDAQ:AMGN),Cell Therapeutics, Inc.(NASDAQ:CTIC), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.html.

Follow us on Twitter atwww.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division ofRainbow Coral Corp.(OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visitwww.RainbowBioSciences.com/investors.html.

See more here:
RBCC Anticipates Favorable Test Results of New Brain Injury Treatment

Related Posts
This entry was posted in Brain Injury Treatment. Bookmark the permalink.

Comments are closed.